ABSTRACT
In this placebo-controlled phase II randomized clinical trial, 103 human immunodeficiency virus type 1 (HIV-1)-infected patients under cART (combined antiretroviral treatment) were randomized 2:1 to receive either 3 doses of DNA GTU-MultiHIV B (coding for Rev, Nef, Tat, Gag, and gp160) at week 0 (W0), W4, and W12, followed by 2 doses of LIPO-5 vaccine containing long peptides from Gag, Pol, and Nef at W20 and W24, or placebo. Analytical treatment interruption (ATI) was performed between W36 to W48. At W28, vaccinees experienced an increase in functional CD4+ T-cell responses (P < 0.001 for each cytokine compared to W0) measured, predominantly against Gag and Pol/Env, and an increase in HIV-specific CD8+ T cells producing interleukin 2 (IL-2) and tumor necrosis factor alpha (TNF-α) (P = 0.001 and 0.013, respectively), predominantly against Pol/Env and Nef. However, analysis of T-cell subsets by mass cytometry in a subpopulation showed an increase in the W28/W0 ratio for memory CD8+ T cells coexpressing exhaustion and senescence markers such as PD-1/TIGIT (P = 0.004) and CD27/CD57 (P = 0.044) in vaccinees compared to the placebo group. During ATI, all patients experienced viral rebound, with the maximum observed HIV RNA level at W42 (median, 4.63 log10 copies [cp]/ml; interquartile range [IQR], 4.00 to 5.09), without any difference between arms. No patient resumed cART for CD4 cell count drop. Globally, the vaccine strategy was safe. However, a secondary HIV transmission during ATI was observed. These data show that the prime-boost combination of DNA and LIPO-5 vaccines elicited broad and polyfunctional T cells. The contrast between the quality of immune responses and the lack of potent viral control underscores the need for combined immunomodulatory strategies. (This study has been registered at ClinicalTrials.gov under registration no. NCT01492985.)IMPORTANCE In this placebo-controlled phase II randomized clinical trial, we evaluated the safety and immunogenicity of a therapeutic prime-boost vaccine strategy using a recombinant DNA vaccine (GTU-MultiHIV B clade) followed by a boost vaccination with a lipopeptide vaccine (HIV-LIPO-5) in HIV-infected patients on combined antiretroviral therapy. We show here that this prime-boost strategy is well tolerated, consistently with previous studies in HIV-1-infected individuals and healthy volunteers who received each vaccine component individually. Compared to the placebo group, vaccinees elicited strong and polyfunctional HIV-specific CD4+ and CD8+ T-cell responses. However, these immune responses presented some qualitative defects and were not able to control viremia following antiretroviral treatment interruption, as no difference in HIV viral rebound was observed in the vaccine and placebo groups. Several lessons were learned from these results, pointing out the urgent need to combine vaccine strategies with other immune-based interventions.
Subject(s)
AIDS Vaccines , Anti-Retroviral Agents/therapeutic use , HIV Infections/therapy , Vaccines, DNA , AIDS Vaccines/administration & dosage , AIDS Vaccines/immunology , Adult , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/immunology , Female , HIV Infections/immunology , HIV-1/drug effects , Humans , Immunization, Secondary , Male , Middle Aged , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunologyABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has become a major public health issue worldwide. Developing and evaluating rapid and easy-to-perform diagnostic tests is a high priority. The current study was designed to assess the diagnostic performance of an antigen-based rapid detection test (COVID-VIRO®) in a real-life setting. Two nasopharyngeal specimens of symptomatic or asymptomatic adult patients hospitalized in the Infectious Diseases Department or voluntarily accessing the COVID-19 Screening Department of the Regional Hospital of Orléans, France, were concurrently collected. The diagnostic specificity and sensitivity of COVID VIRO® results were compared to those of real-time reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) results. A subset of patients underwent an additional oropharyngeal and/or saliva swab for rapid testing. A total of 121 patients confirmed to be infected and 127 patients having no evidence of recent or ongoing infection were enrolled for a total of 248 nasopharyngeal swab specimens. Overall, the COVID-VIRO® sensitivity was 96.7% (CI, 93.5%-99.9%). In asymptomatic patients, symptomatic patients having symptoms for more than 4 days and those with an RT-qPCR cycle threshold value ≥ 32, the sensitivities were 100%, 95.8%, and 91.9%, respectively. The concordance between RT-qPCR and COVID VIRO® rapid test results was 100% for the 127 patients with no SARS-CoV-2 infection. The COVID-VIRO® test had 100% specificity and sensitivity greater than 95%, which are better than the recommendations set forth by the WHO (specificity ≥ 97%-100%, sensitivity ≥ 80%). These rapid tests may be particularly useful for large-scale screening in emergency departments, low-resource settings, and airports.
Subject(s)
Antigens, Viral/isolation & purification , COVID-19 Testing/methods , COVID-19/diagnosis , Nasopharynx/virology , SARS-CoV-2/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Point-of-Care Testing , Sensitivity and Specificity , Young AdultABSTRACT
BACKGROUND: HIV pre-exposure prophylaxis (PrEP) was implemented in France in November 2015 based on individual-level risk factors for HIV infection. We evaluated the proportion of missed opportunities for PrEP among newly HIV-diagnosed people entering the Dat'AIDS cohort in 2016. METHODS: Multicenter retrospective analysis in 15 French HIV clinical centers of patients with a new diagnosis of HIV infection. Among them we differentiated patients according to the estimated date of infection: those occurring in the PrEP area (a previous negative HIV test in the last 12 months or those with an incomplete HIV-1 western blot (WB) with no HIV-1 anti-Pol-antibody at time of HIV diagnosis) and those in the pre-PrEP area (older infections). Epidemiological, biological and clinical data at HIV diagnosis were collected. Clinicians retrospectively identified potential eligibility for PrEP based on individual-level risk factors for HIV infection among those infected in the PrEP area. RESULTS: Among 966 patients with a new HIV diagnosis, 225 (23.3%) were infected in the PrEP area and 121 (53.8%) had complete data allowing evaluation of PrEP eligibility. Among them, 110 (91%) would have been eligible for PrEP, median age 31 years, with 68 (75.6%) born in France and 10 (11.1%) in Central/West Africa, with more than one previous STI in 19 (15.7%). The main eligibility criteria for PrEP were being a man who had sex with men or transgender 91 (82.7%) with at least one of the following criteria: unprotected anal sex with ≥2 partners in the last 6 months: 67 (60.9%); bacterial sexually transmitted infection in the last 12 months: 33 (30%); Use of psychoactive substances in a sexual context (chemsex): 16 (14.5%). PrEP was indicated for other HIV risk factors in 25 (22.7%). CONCLUSION: With 91% (110/121) of patients infected in the PrEP area eligible for PrEP, this study highlights the high potential of PrEP in avoiding new infection in France but also shows a persistent delay in HIV testing. Thus, an important limit on PrEP implementation in France could be insufficient screening and care access.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/prevention & control , Pre-Exposure Prophylaxis , AIDS Serodiagnosis , Adult , Africa, Western , Cohort Studies , Delayed Diagnosis , Female , France , HIV-1 , Homosexuality, Male , Humans , Male , Middle Aged , Retrospective Studies , Sexual Behavior , Sexual Partners , Transgender Persons , Unsafe SexABSTRACT
Antibiotic (ATB) treatment of critically ill patients with pathophysiological injuries remains a challenge due to the constant increase in antimicrobial resistance. Therapeutic drug monitoring (TDM) is advised for ATB dose adjustments to avoid suboptimal concentrations and dose-related adverse effects. Therefore, a single and reliable analytical method for a broad selection of ATBs was developed using a high-resolution mass spectrometry (HRMS) platform for frequent use in intensive care units. An UHPLC assay coupled to high resolution accurate mass acquisition has been developed for the quantification of penicillins (amoxicillin, oxacillin, piperacillin, and ticarcillin), cephalosporines (cefepime, cefotaxime, ceftazidime, and ceftriaxone), carbapenems (ertapenem, imipenem, and meropenem), lincosamide (clindamycin), quinolones (ofloxacin and ciprofloxacin) and tazobactam. Plasma samples (100µL) were spiked with an internal standard solution followed by protein precipitation. Separation was achieved on an Accucore C18 column, which enabled sample analysis every 9min. All compounds were detected in electrospray positive ion mode and quantified with a linear regression between 0.5 and 32mg/L (r2>0.998). Overall precision and accuracy did not exceed 15%. No significant matrix effect was observed for the studied ATBs. Stored stock solutions at -20°C were stable for 6 months, except for amoxicillin and imipenem. Analytes in plasma were stable for 24h under ambient conditions as well as in post-preparation in an autosampler, except for amoxicillin and imipenem. This HRMS assay provides the simultaneous quantification of 15 ATB; it fulfills the usual quality criteria and was successfully applied for routine TDM of ATBs. The method is based on a full scan acquisition, and it would be easy to add other compounds to the present panel in the future, as this assay has already been proven to be efficient for different classes of compounds.
Subject(s)
Anti-Bacterial Agents/blood , Chromatography, High Pressure Liquid/methods , Drug Monitoring/methods , Mass Spectrometry/methods , Humans , Limit of Detection , Linear Models , Reproducibility of ResultsABSTRACT
Primary Epstein-Barr virus infection (PEI) is acquired increasingly later in life in developed countries, involving a growing number of adults. No studies have examined the effect of age on PEI. We conducted a prospective, single-centre, noninterventional survey to assess the clinical and economic effects of PEI care according to age. We included all serology-confirmed cases observed in all departments of a large regional hospital. Clinical and biologic data, therapeutics and costs of care were examined. Over a 6-year period, we included 292 subjects (148 children and 144 adults) with a median age of 15.4 years (range 9 months to 79 years). Adults were hospitalized more often (83% vs. 60%) and for longer periods of time (median 4 days vs. 2 days) than children (p ≤ 0.0001 for both). Two adults required a secondary transfer into the intensive care unit, although no children did. Typically, adults showed higher levels of activated lymphocytes and liver abnormalities. They also required the use of systemic corticosteroids more often (45% vs. 23%, p < 0.0001) and for longer periods of time (median 7 days vs. 3 days, p 0.02) than children. Overall, the costs were significantly higher for adults than for children (median, 1940 vs. 1130, p < 0.0001), mainly because of the frequency and duration of hospitalizations. Age increases the immune response and clinical severity of PEI, resulting in substantial additional costs for the community. Better recognition of the disease in adults could shorten the average length of hospital stay.
Subject(s)
Epstein-Barr Virus Infections/epidemiology , Epstein-Barr Virus Infections/pathology , Hospitalization , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Age Factors , Aged , Anti-Inflammatory Agents/therapeutic use , Child , Child, Preschool , Epstein-Barr Virus Infections/economics , Female , France/epidemiology , Health Care Costs , Humans , Infant , Length of Stay , Male , Middle Aged , Prospective Studies , Young AdultABSTRACT
Massive loss of lamina propria CD4(+) T cells, changes in the lymphatic architecture, and altered intestinal epithelial barrier leading to microbial translocation are the common features of HIV-1 infection and are not fully restored under combined antiretroviral therapy (cART). To better understand determinants of gut mucosal restoration, we have performed phenotypic and gene expression analyses of the gut from HIV-infected patients, naive or treated with cART initiated either at the early phase of the primary infection or later during the chronic phase. We found a depletion of T helper type 22 (Th22) and interleukin-17-producing cells in naive patients. These populations, except Th22 cells, were not restored under cART. Regulatory T cells/Th17 ratio was significantly increased in HIV-infected patients and was inversely correlated to the restoration of CD4(+) T cells but not to gut HIV DNA levels. Gene profile analysis of gut mucosal distinguished two groups of patients, which fitted with the timing of cART initiation. In their majority early, but not later treated patients, exhibited conserved intestinal lymphoid structure, epithelial barrier integrity and dendritic cell maturation pathways. Our data demonstrate that early initiation of cART helps to preserve and/or restore lymphoid gut mucosal homeostasis and provide a rationale for initiating cART during the acute phase of HIV infection.
Subject(s)
Anti-Retroviral Agents/therapeutic use , Dendritic Cells/drug effects , HIV Infections/drug therapy , HIV-1/drug effects , Intestines/drug effects , T-Lymphocytes, Regulatory/drug effects , Th17 Cells/drug effects , Cell Differentiation/drug effects , Cells, Cultured , DNA, Viral/blood , Dendritic Cells/immunology , Dendritic Cells/virology , Disease Progression , Drug Therapy, Combination , Female , Gene Expression Profiling , HIV Infections/immunology , HIV-1/physiology , Humans , Immunity, Mucosal/drug effects , Interleukins/metabolism , Intestines/immunology , Intestines/virology , Male , Middle Aged , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/virology , Th17 Cells/immunology , Th17 Cells/virology , Treatment Outcome , Interleukin-22Subject(s)
Anti-Infective Agents/adverse effects , Brain Diseases/chemically induced , Metronidazole/adverse effects , Olivary Nucleus/drug effects , Brain Abscess/drug therapy , Follow-Up Studies , Fusobacterium Infections/drug therapy , Fusobacterium nucleatum/drug effects , Humans , Hypertrophy , Magnetic Resonance Imaging , Male , Middle Aged , Olivary Nucleus/pathologyABSTRACT
We report the case of a 55 year-old man presenting with a double aortic and mitral endocarditis for which resected valve culture was repeatedly negative. Specific PCR made on valves because of highly positive blood tests for Bartonella henselae remained negative. A molecular approach was made with 16S rDNA PCR, followed by sequencing. Bartonella quintana was identified as the etiology of endocarditis. B. quintana, "fastidious" bacteria, even if hard to identify in a laboratory, is often reported as a blood culture negative endocarditis (BCNE) agent. Molecular biology methods have strongly improved the diagnosis of BCNE. We propose a review of the literature focusing on the interest of broad-spectrum PCR on valve for the etiological diagnosis of BCNE.
Subject(s)
Bartonella quintana/isolation & purification , DNA, Bacterial/analysis , Endocarditis, Bacterial/etiology , Polymerase Chain Reaction/methods , RNA, Ribosomal, 16S/genetics , Ribotyping , Trench Fever/diagnosis , Agricultural Workers' Diseases/blood , Agricultural Workers' Diseases/diagnosis , Agricultural Workers' Diseases/etiology , Agricultural Workers' Diseases/microbiology , Aortic Valve/microbiology , Aortic Valve/surgery , Bartonella quintana/genetics , Blood/microbiology , Endocarditis, Bacterial/blood , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/surgery , False Negative Reactions , Gardening , Heart Valve Prosthesis Implantation , Humans , Male , Middle Aged , Mitral Valve/microbiology , Mitral Valve/surgery , Phylogeny , Sequence Homology, Nucleic Acid , Trench Fever/complicationsABSTRACT
Thyroid abnormalities and Takayasu arteritis (TA) have been reported separately in patients with Crohn disease (CD). We report two patients with hyperthyroidism, CD and Takayasu arteritis and discuss hypothetical mechanisms. Case 1. A thyrotoxic goiter was diagnosed in 1987 in a 34-year-old woman treated since 1969 for severe CD and TA. Iodine urinary excretion was 405 microg/mL (20-500). Anti-thyrotropin receptor (TRAK) and anti-thyroid antibodies were not detectable. The ultrasonography showed a nodule in the right lobe of the thyroid and two nodules in the left lobe. A 123I thyroid scan showed a multinodular goiter with no hot nodule. She was treated successfully with propylthiouracile until 1991, when a new episode of thyrotoxicosis led to a subtotal thyroidectomy. Case 2. Hyperthyroidism was diagnosed in February 2000 in a 49-year-old woman treated for CD and TA, both diagnosed in 1980. TRAK and anti-thyroid peroxydase antibodies were not detectable. The ultrasonography disclosed a normal thyroid volume with an inhomogeneous parenchymal structure and nodular images in both lobes. A 123I thyroid scan showed one hot nodule in the lower part of each lobe. A subtotal thyroidectomy was performed. The association of these three diseases may not be fortuitous, possibly explained by genetic predisposing factors and disease-related iodine deficiency both involving Nuclear Factor kappaB pathway.
Subject(s)
Crohn Disease/complications , Hyperthyroidism/etiology , Takayasu Arteritis/complications , Adult , Crohn Disease/physiopathology , Female , Humans , Hyperthyroidism/physiopathology , Middle Aged , Takayasu Arteritis/physiopathologyABSTRACT
OBJECTIVE: We describe the prevalence, risk factors and outcome of hyperlactataemia (HL) in a cohort of 140 HIV-infected patients. PATIENTS AND METHODS: Patients were enrolled consecutively within a 3-month period (July to September 1999) and followed until 31 October 2000. One hundred and forty HIV-infected patients had venous plasma lactate levels measured. HL was defined at baseline by two consecutive lactate levels > 2.1 mmol/L (upper limit of normal). We compared baseline demographic characteristics, immuno-virological parameters, antiretroviral therapy and outcome between patients with HL (cases) or without HL (controls). We described the clinical features of patients with HL. RESULTS: Among 129 patients included in the analysis, HL was found in 11 patients (8.5%), all of whom were receiving nucleoside reverse transcriptase inhibitors (NRTIs). Cases were more likely than controls to receive didanosine or stavudine (82% vs. 19%, P= 2.7 x 10(-6) and 82% vs. 48%, P= 0.03, respectively). Only 4/11 cases (36%) had symptoms consistent with HL. After a median follow-up of 15 months, lactate level returned to normal in all three patients who discontinued NRTIs, but in only 2/8 patients who did not (P = 0.06). Only one case experienced lactic acidosis and died during follow-up. Mortality rate was similar in cases and controls. CONCLUSION: HL is associated with NRTI use, in particular didanosine and stavudine, and discontinuation of NRTIs seems to be associated with rapid resolution of HL. Lactic acidosis remains rare and the long-term outcome of patients with HL does not seem to be poorer than controls.
Subject(s)
HIV Infections/blood , Lactic Acid/blood , Acidosis, Lactic/chemically induced , Adult , Anti-HIV Agents/adverse effects , Didanosine/adverse effects , Female , Follow-Up Studies , HIV Infections/drug therapy , Humans , Male , Middle Aged , Prevalence , Prognosis , Prospective Studies , Reverse Transcriptase Inhibitors/adverse effects , Risk Factors , Stavudine/adverse effectsABSTRACT
INTRODUCTION: Drepanocytosis, even severe, may only be discovered in adults further to severe complications. OBSERVATION: A 44 year-old woman was hospitalised for a severe vaso-occlusive crisis, revealing a drepanocyte syndrome with heterozygote S-beta zero thalassemia. Evolution was marked by severe anaemia, the aregenerative nature of which, uncommon during vaso-occlusive crises and the absence of Parvovirus B19 infection, led to the diagnosis of medullar necrosis. Evolution was rapidly improved after transfusion of erythrocyte concentrations and symptomatic treatment of the pain. COMMENTS: Medullar necrosis is a rare entity with multiple causes. In severe drepanocyte syndromes it is concomitant to a severe vaso-occlusive syndrome, resulting from medullar ischemia due to specific microvascular damage.
Subject(s)
Anemia, Sickle Cell/complications , Kidney Medulla/pathology , Adult , Anemia, Sickle Cell/diagnosis , Blood Transfusion , Female , Humans , Necrosis , Pain , Thalassemia/etiology , Thalassemia/pathology , Vascular Diseases/etiology , Vascular Diseases/pathologyABSTRACT
Although central nervous system involvement in disseminated aspergillosis is known to occur in immunocompromised patients, particularly after bone marrow transplantation, localized involvement of the spinal cord is exceedingly rare. In this report we present and illustrate detailed imaging findings of central nervous system invasion by Aspergillus fumigatus in a 30-year-old woman, with emphasis on the spinal cord involvement.
Subject(s)
Aspergillus fumigatus/isolation & purification , Cerebral Infarction/diagnosis , Neuroaspergillosis/diagnosis , Spinal Cord Diseases/diagnosis , Adult , Bone Marrow Transplantation , Cerebral Cortex/pathology , Cerebral Infarction/microbiology , Fatal Outcome , Female , Humans , Leukemia, Myeloid/complications , Neuroaspergillosis/etiology , Spinal Cord/pathology , Spinal Cord Diseases/microbiologySubject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Antidepressive Agents, Second-Generation/poisoning , Antiretroviral Therapy, Highly Active/adverse effects , Depressive Disorder/drug therapy , Drug Overdose/diagnosis , Drug Resistance, Multiple, Viral , Maprotiline/poisoning , Acquired Immunodeficiency Syndrome/parasitology , Acquired Immunodeficiency Syndrome/virology , Adult , Antidepressive Agents, Second-Generation/administration & dosage , Cytochrome P-450 CYP2D6 Inhibitors , Drug Interactions , Electrocardiography/drug effects , Humans , Male , Maprotiline/administration & dosageABSTRACT
SETTING: Saint Louis Hospital, Paris, France. OBJECTIVE: To determine the clinical relevance of detection of Mycobacterium tuberculosis DNA by nested polymerase chain reaction (PCR) in peripheral blood mononuclear cells (PBMCs) in the rapid diagnosis of tuberculosis. DESIGN: Single-centre prospective case study of 90 hospitalised patients and 50 healthy subjects or blood donors from 1 January to 30 June 1998. RESULTS: Twenty-three patients were diagnosed with tuberculosis (26.7%); 20 tuberculosis patients were culture-positive, with seven smear-positive for acid-fast bacilli. Sensitivity of smear, culture and nested PCR was 30.4 (7/23), 87 (20/23) and 30.4% (7/23), respectively. The specificity of smear and culture was 100%, and the specificity of the nested PCR was 96% in the healthy subjects. However, the specificity decreased to 83.6% in the hospitalised patients, with 11 nested PCR-positive patients without a diagnosis of tuberculosis. The sensitivity of the nested PCR was low in pulmonary tuberculosis (22.2%), but increased in pulmonary/extra-pulmonary tuberculosis (50%), extra-pulmonary tuberculosis (33%), and disseminated tuberculosis (33%). CONCLUSION: The use of a nested PCR assay on PBMC may pose problems for the rapid diagnosis of tuberculosis with regard to low sensitivity and specificity. However, further studies are needed to confirm this technique as an alternative test for the diagnosis of paucibacillary forms of tuberculosis.
Subject(s)
DNA, Bacterial/genetics , Leukocytes, Mononuclear/microbiology , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Polymerase Chain Reaction , Tuberculosis/blood , Tuberculosis/genetics , Adult , Aged , Aged, 80 and over , Case-Control Studies , Culture Media , Female , Humans , Male , Middle Aged , Prospective Studies , Sensitivity and Specificity , Time FactorsABSTRACT
BACKGROUND: Infection of the residual cavity after pneumonectomy generally occurs early after surgery. CASE REPORT: A 67-year old patient was hospitalized with fever 16 years after pneumonectomy for lung cancer. Investigations led to the diagnosis of infection of the pneumonectomy cavity. DISCUSSION: Late infection several years after pneumonectomy is exceptional and usually occurs in a setting of bacteriemia. Diagnosis is difficult due to modifications of the thoracic signs but should be entertained whenever unexplained fever or an inflammatory syndrome occurs in a pneumonectomized patient. The thoracic CT scan shows an abnormally enlarged cavity. Bacteriological examination of evacuated fluid provides the key to diagnosis. Drainage-lavage is indicated. Surgery may be needed exceptionally.
Subject(s)
Carcinoma, Squamous Cell/surgery , Lung Neoplasms/surgery , Pneumonectomy , Surgical Wound Infection/diagnostic imaging , Tomography, X-Ray Computed , Aged , Follow-Up Studies , Humans , Male , Reoperation , Surgical Wound Infection/surgerySubject(s)
Acquired Immunodeficiency Syndrome/complications , Antineoplastic Agents/therapeutic use , Antiviral Agents/therapeutic use , Cytosine/therapeutic use , Interferon-alpha/therapeutic use , Lymphoma, B-Cell/drug therapy , Organophosphonates , Organophosphorus Compounds/therapeutic use , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/physiopathology , AIDS-Related Opportunistic Infections/virology , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/physiopathology , Acquired Immunodeficiency Syndrome/virology , Adult , Antiretroviral Therapy, Highly Active , Burkitt Lymphoma/drug therapy , Burkitt Lymphoma/physiopathology , Burkitt Lymphoma/virology , Cidofovir , Cytosine/analogs & derivatives , HIV Long-Term Survivors , HIV Protease Inhibitors/therapeutic use , Herpesvirus 4, Human/isolation & purification , Herpesvirus 8, Human/isolation & purification , Humans , Lymphoma, B-Cell/physiopathology , Lymphoma, B-Cell/virology , Male , Pleural Effusion , Sarcoma, Kaposi/drug therapy , Sarcoma, Kaposi/physiopathology , Sarcoma, Kaposi/virology , Time FactorsABSTRACT
Fourteen cases of severe acyclovir-resistant herpes simplex virus type 1 (HSV-1) infection, 7 of which showed resistance to foscarnet, were diagnosed among 196 allogeneic stem cell transplant recipients within a 29-month period. Recipients of unrelated stem cell transplants were at higher risk. All patients received foscarnet; 8 subsequently received cidofovir. Strains were initially foscarnet-resistant in 3 patients and secondarily so in 4 patients. In vitro resistance to acyclovir or foscarnet was associated with clinical failure of these drugs; however, in vitro susceptibility to foscarnet was associated with complete response in only 5 of 7 patients. No strain from any of the 7 patients was resistant in vitro to cidofovir; however, only 3 of 7 patients achieved complete response. Therefore, acyclovir- and/or foscarnet-resistant HSV-1 infections after allogeneic stem cell transplantation have become a concern; current strategies need to be reassessed and new strategies must be evaluated in this setting.
Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Herpes Simplex/drug therapy , Herpes Simplex/etiology , Organophosphonates , Acyclovir/therapeutic use , Adolescent , Adult , Antiviral Agents/therapeutic use , Child , Cidofovir , Cytosine/analogs & derivatives , Cytosine/therapeutic use , Drug Resistance, Microbial , Female , Foscarnet/therapeutic use , Herpes Simplex/virology , Herpesvirus 1, Human/drug effects , Herpesvirus 1, Human/isolation & purification , Humans , Male , Middle Aged , Organophosphorus Compounds/therapeutic use , Transplantation, HomologousABSTRACT
We report the first 2 cases of fatal invasive aspergillosis complicating severe malaria. In 2 nonimmune European adults without underlying disease, death was directly ascribable to invasive aspergillosis. We believe that transient malaria-induced immunosuppression allowed massive growth and overwhelming dissemination of preexisting Aspergillus colonization.